CAS: 16009-13-5; 1,3,5,8-Tetramethyl-2,4-Divinylporphine-6,7-Dipropionic Acid Ferrichloride

上下游产品

L-glutamic acid protoporphyrin IXheme b ferriprotoporphyrin IX hydroxide protoporphyrin IX dimethyl ester γ dimethyl esterbiliverdin IXγ dimethyl ester

专利信息

专利号:US-5935570-A
优先权日:1995-10-20
标 题 :Synthesis of immunologic, therapeutic and prophylactic compounds by transformed clavibacter
发明人：KOPROWSKI HILARY; CARLSON PETER SPIKINS; HOOPER DOUGLAS CRAIG; CONWAY LAURA JANE; MICHAELS FRANK H; MODELSKA ANNA; FU ZHEN FANG
权利人:UNIV JEFFERSON
摘要:A process for the synthesis and delivery of bioactive compounds, compounds that have a therapeutic, biochemical, or immunologic, effect on an animal, such as human. In the process, clavibacter is genetically altered so that it synthesizes the bioactive compound. A plant may be infected with the genetically altered clavibacter and used an as oral delivery system.

专利号:US-11033507-B2
优先权日:2013-12-19
标 题 :Method of synthesis of silica vesicles and use thereof
发明人：YU CHENGZHONG; MITTER NEENA; ZHANG JUN
权利人:UNIV QUEENSLAND
摘要:The invention relates, in part, to a method of producing silica vesicles including under controlled conditions to thereby heavily influence the morphology and characteristics of the vesicles. The vesicles are shown to be effective as delivery agents for chemical and biological agents. They are also shown to be useful in methods of treatment and as components of an immunogenic composition.

专利号:US-8871926-B1
优先权日:2010-09-28
标题:Synthesis of porphyrin nanostructures
发明人：FAN HONGYOU; BAI FENG
权利人:FAN HONGYOU; BAI FENG; SANDIA CORP
摘要:The present disclosure generally relates to self-assembly methods for generating porphyrin nanostructures. For example, in one embodiment a method is provided that includes preparing a porphyrin solution and a surfactant solution. The porphyrin solution is then mixed with the surfactant solution at a concentration sufficient for confinement of the porphyrin molecules by the surfactant molecules. In some embodiments, the concentration of the surfactant is at or above its critical micelle concentration (CMC), which allows the surfactant to template the growth of the nanostructure over time. The size and morphology of the nanostructures may be affected by the type of porphyrin molecules used, the type of surfactant used, the concentration of the porphyrin and surfactant the pH of the mixture of the solutions, and the order of adding the reagents to the mixture, to name a few variables.

专利号:EP-1476197-B1
优先权日:2002-02-22
标题 :Synthesis of lipopolysaccharide-protein conjugate vaccines via the lipid a region following removal of the glycosidic phosphate residue
发明人：JENNINGS HAROLD; MIESZALA MALGORZATA; KOGAN GRIGORIJ; ZOU WEI; RICHARDS JAMES C; COX ANDREW; MOXON RICHARD
权利人:CA NAT RESEARCH COUNCIL
摘要:This invention relates to lipopolysaccharide-protein conjugate vaccines with appropriate presentation of conserved inner core oligosaccharide epitopes having improved immunogenic properties. These are based upon antigenic, detoxified bacterial lipopolysaccharides which optimally present an inner core oligosaccharide epitope following removal of at least a glycosidic phosphate of the lipid A region. These partially or completely dephosphorylated antigenic, detoxified bacterial lipopolysaccharides are linkable to an immunologically acceptable carrier and can be used in polyvalent or multivalent vaccines.

专利号:US-2024285670-A1
优先权日:2021-06-11
标题 :Therapeutic treatment of tumors by blocking the heme synthesis-export axis
发明人：TOLOSANO EMANUELA; FIORITO VERONICA; PETRILLO SARA; CHIABRANDO DEBORAH; ALLOCCO ANNA LUCIA; BERTINO FRANCESCA
权利人:UNIV DEGLI STUDI DI TORINO
摘要:A blocker of heme synthesis-export axis as active agent for use in the treatment of a tumor in a subject, wherein the blocker of heme synthesis-export axis upmodulates oxidative metabolism of tumor cells by upregulating the tricarboxylic acid (TCA) cycle and the oxidative phosphorylation (OXPHOS).

专利号:US-2005147624-A1
优先权日:2002-02-22
标题 :Synthesis of lipopolysaccharide-protein conjugate vaccines via the lipid a region following removal of the glycosidic phosphate residue